Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Janosi, J
Right arrow Articles by Valyi-Nagy, I
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Janosi, J
Right arrow Articles by Valyi-Nagy, I
Haematologica, Vol 89, Issue 3, 370-371
Copyright © 2004 by Ferrata Storti Foundation

Letter

Soluble syndecan-1 levels in different plasma cell dyscrasias and in different stages of multiple myeloma

J Janosi, A Sebestyen, G Mikala, J Nemeth, Z Kiss, and I Valyi-Nagy

We measured serum levels of syndecan-1 in patients with multiple myeloma (MM), solitary plasmocytoma and monoclonal gammopathy of undetermined significance (MGUS). We then studied serum syndecan-1 levels in MM patients stratified by the Durie-Salmon staging system and the correlation of syndecan-1 levels with well known independent prognostic factors of MM.




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.